{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=91", "query": { "condition": "Relapsed, Refractory Malignant Neoplasms", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 3448, "total_pages": 345, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T22:16:45.386Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00659984", "title": "N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "UltratraceTM Iobenguane I 131 Imaging", "type": "DRUG" }, { "name": "UltratraceTM Iobenguane I 131 Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Insight Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 15, "start_date": "2008-06", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-10-04", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659984" }, { "nct_id": "NCT02375204", "title": "Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Germ Cell Tumor", "Teratoma", "Choriocarcinoma", "Germinoma", "Mixed Germ Cell Tumor", "Yolk Sac Tumor", "Childhood Teratoma", "Malignant Germ Cell Neoplasm", "Extragonadal Seminoma", "Non-seminomatous Germ Cell Tumor", "Seminoma" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "pegylated G-CSF", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "stem cell reinfusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "MALE", "summary": "14 Years and older · Male only" }, "enrollment_count": 420, "start_date": "2015-08-06", "completion_date": "2031-06-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375204" }, { "nct_id": "NCT07424833", "title": "A Study of APG-3288 in Relapsed/Refractory Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Hematological Malignancies", "Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL", "Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)", "Relapsed/Refractory Mantle Cell Lymphoma (MCL)", "Relapsed/Refractory Waldenström Macroglobulinemia (WM)", "Relapsed/Refractory Marginal Zone Lymphoma (MZL)", "Relapsed/Refractory Follicular Lymphoma (FL)" ], "interventions": [ { "name": "APG-3288", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-03-10", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 5, "location_summary": "Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424833" }, { "nct_id": "NCT02899052", "title": "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2017-01-19", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02899052" }, { "nct_id": "NCT00062244", "title": "Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062244" }, { "nct_id": "NCT01246063", "title": "Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2012-05-14", "completion_date": "2018-03-23", "has_results": true, "last_update_posted_date": "2019-04-08", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01246063" }, { "nct_id": "NCT01342887", "title": "Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "pravastatin sodium", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-04", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342887" }, { "nct_id": "NCT04315324", "title": "Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent T Acute Lymphoblastic Leukemia", "Refractory T Acute Lymphoblastic Leukemia", "Refractory T Lymphoblastic Lymphoma", "T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "AKR1C3-activated Prodrug AST-3424", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 67, "start_date": "2021-02-08", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 163, "location_summary": "Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315324" }, { "nct_id": "NCT00005946", "title": "Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005946" }, { "nct_id": "NCT04639024", "title": "ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Myeloproliferative Neoplasm (MDS/MPN)" ], "interventions": [ { "name": "ADCT-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gwynn Long, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-12-07", "completion_date": "2022-11-03", "has_results": true, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-26T22:16:45.386Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639024" } ] }